Solara Active Pharma Sciences Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Thu Apr 09 2026

Solara Active Pharma Sciences (NSE: SOLARA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 550 — against a 52-week high of Rs 820 and a 1-year return of -28% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 780-850 Cr, with PAT expectations of Rs 30-55 Cr and margin projections of EBITDA 13-16%. This article covers the Solara Active Pharma Sciences Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and the most commonly searched investor questions.

Table of Contents

Solara Active Pharma Sciences Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Solara Active Pharma Sciences has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar:

Company	Results Date	Article
TCS	April 9, 2026	Preview on Univest
Infosys	April 23, 2026	Preview on Univest
Solara Active Pharma Sciences	May 2026 (Expected)	This article

Why This Quarter Matters

Solara Active Pharma Sciences enters Q4 FY26 with expectations of 8-12% YoY revenue growth. Q4 is the final quarter of FY26 — it determines full-year performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -28%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can sustain recovery momentum.

Solara Active Pharma Sciences Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Driver
Revenue	Rs 720 Cr	Rs 780-850 Cr	Volume + pricing
PAT	Rs 18 Cr	Rs 30-55 Cr	Operating leverage
Margin	EBITDA 12.6%	EBITDA 13-16%	Cost control
Key Growth Metric	Q3 trend	8-12% YoY revenue growth	Management execution
Dividend Estimate	—	Nil expected	Board recommendation

A positive surprise on any two of the four key parameters — revenue, margin, guidance, and dividend — could drive a meaningful post-results re-rating.

Screen Solara Active Pharma Sciences fundamentals on Univest Screener.

5 Key Factors That Will Drive Solara Active Pharma Sciences Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 780-850 Cr in Q4 FY26 revenue (Q3: Rs 720 Cr). Q4 is seasonally important for the Pharma/API sector, driven by year-end order execution and government capex push. The ability to convert the pipeline into recognised revenue will be the first test.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 13-16%, versus EBITDA 12.6% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst.

PAT Quality

Net profit is estimated at Rs 30-55 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean, recurring profit print is most positively received by institutional investors.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue bands, margin targets, and capex plans. In the current global macro environment, credible and specific FY27 guidance will be valued more than usual by the market.

Dividend Declaration

Solara Active Pharma Sciences is expected to consider a final dividend of Nil expected. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Solara Active Pharma Sciences Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty across Indian equities. For Solara Active Pharma Sciences, indirect impacts include FII outflows and potential earnings estimate cuts if global demand slows. A tariff negotiation breakthrough remains the most significant macro upside catalyst.

Earnings Miss Risk

If Solara Active Pharma Sciences’s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus the Rs 780-850 Cr estimate and PAT versus Rs 30-55 Cr as the two primary watchpoints on results day.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling pressure would create headwinds for Solara Active Pharma Sciences regardless of company-specific fundamentals.

Sector Regulatory Risk

The Pharma/API sector faces evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Solara Active Pharma Sciences’s profitability beyond current consensus models.

Solara Active Pharma Sciences Share Price and Analyst Ratings

Solara Active Pharma Sciences is trading at Rs 550 as of early April 2026, against a 52-week high of Rs 820 and a 52-week low of Rs 420. Market cap stands at Rs 2,200 Cr. The 1-year return of -28% reflects sector headwinds alongside company-specific factors.

Brokerage	Rating	Target Price	Thesis
MOFSL	Neutral	Rs 600	Ibuprofen + other API; debt overhang
YES Securities	Buy	Rs 650	Turnaround; new CEO driving change
JM Financial	Add	Rs 620	EBITDA recovery from FY25 trough
Emkay	Neutral	Rs 580	High leverage; cautious stance

Download the Univest iOS App or Univest Android App to track Solara Active Pharma Sciences’s live price and receive real-time Q4 result alerts.

Conclusion

Solara Active Pharma Sciences Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma/API sector. Analysts project PAT of Rs 30-55 Cr and revenue of Rs 780-850 Cr. At a CMP of Rs 550 and analyst targets ranging from Rs 580 to Rs 600, the stock offers meaningful risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews, visit Univest Blogs.

Frequently Asked Questions

What is the Solara Active Pharma Sciences Q4 results 2026 date?

The Solara Active Pharma Sciences Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.

What is the Solara Active Pharma Sciences Q4 FY26 PAT estimate?

Analysts estimate Solara Active Pharma Sciences Q4 FY26 PAT at Rs 30-55 Cr, based on revenue of Rs 780-850 Cr and margin of EBITDA 13-16%. Actual results may differ from consensus.

What is Solara Active Pharma Sciences’s share price ahead of Q4 results?

Solara Active Pharma Sciences is trading at Rs 550. The 52-week high is Rs 820 and low is Rs 420. The 1-year return is -28% and market cap is Rs 2,200 Cr.

Will Solara Active Pharma Sciences declare a dividend in Q4 FY26?

Solara Active Pharma Sciences is expected to consider a final dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Solara Active Pharma Sciences?

YES Securities (Buy, Rs 650), JM Financial (Add, Rs 620) have positive ratings heading into Q4 FY26.

What were Solara Active Pharma Sciences Q3 FY26 results?

Solara Active Pharma Sciences reported Q3 FY26 revenue of Rs 720 Cr and PAT of Rs 18 Cr, with margin at EBITDA 12.6%. These form the baseline for Q4 FY26 estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is Solara Active Pharma Sciences a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Solara Active Pharma Sciences has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor. Use the Univest Screener to assess fundamentals independently.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.